NCT06524063View on ClinicalTrials.gov

Targeted Survivin DC Cell Injection for the Treatment of GBM

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

October 1, 2027

Conditions
Glioblastoma
Interventions
DRUG

Survivin-loaded dendritic cell injection

The injections will be given on days 0, 14, and 28. The administration will involve both intradermal (ID) and intravenous (IV) routes.

Sponsors
All Listed Sponsors
lead

Beijing Tricision Biotherapeutics Inc

INDUSTRY